Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis

Based on promising results in preclinical models, clinical trials have been performed to evaluate the efficacy of the first-in-class proteasome inhibitor bortezomib towards malignant pleural mesothelioma (MPM), an aggressive cancer arising from the mesothelium of the serous cavities following exposu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerruti, Fulvia, Jocollè, Genny, Salio, Chiara, Oliva, Laura, Paglietti, Luca, Alessandria, Beatrice, Mioletti, Silvia, Donati, Giovanni, Numico, Gianmauro, Cenci, Simone, Cascio, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732203/
https://www.ncbi.nlm.nih.gov/pubmed/29247244
http://dx.doi.org/10.1038/s41598-017-17977-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732203/
https://www.ncbi.nlm.nih.gov/pubmed/29247244
http://dx.doi.org/10.1038/s41598-017-17977-9

Ejemplares similares